Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

4.8%

1 terminated out of 21 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

10%

2 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed with results

Key Signals

4 with results83% success

Data Visualizations

Phase Distribution

9Total
Not Applicable (3)
P 1 (1)
P 2 (3)
P 4 (2)

Trial Status

Recruiting8
Completed5
Unknown3
Not Yet Recruiting3
Active Not Recruiting1
Terminated1

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT03117010RecruitingPrimary

Prospective Cohort for Adult Hemophagocytosis

NCT06160791Phase 2RecruitingPrimary

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

NCT05277272RecruitingPrimary

INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH)

NCT05898477Recruiting

Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis

NCT05236764Not ApplicableActive Not Recruiting

Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion

NCT05146336Recruiting

CytOSorb TreatMent Of Critically Ill PatientS Registry

NCT04902807Recruiting

Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation

NCT07034209Phase 2CompletedPrimary

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))

NCT05882175Recruiting

Prospective Validation of the OHI Index

NCT06047210CompletedPrimary

Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis

NCT06585124Recruiting

Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With Lymphomas

NCT06504030Phase 4Not Yet RecruitingPrimary

Modified DEP Regimens for the Treatment of Hemophagocytic Lymphohistiocytosis

NCT06491719Not ApplicableNot Yet Recruiting

A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT

NCT03546101Completed

Early Detection of Epstein-Barr Virus Related Disease.

NCT03985423Phase 2TerminatedPrimary

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH

NCT03513328Phase 1Completed

Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation

NCT05988177Not ApplicableNot Yet Recruiting

Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections

NCT05531721CompletedPrimary

HLH Patients - a Retrospective Study

NCT05677178UnknownPrimary

Response Prediction in EBV-HLH Using Metabonomics Analysis

NCT05600959UnknownPrimary

Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLH

Scroll to load more

Research Network

Activity Timeline